Amgen and Allergan said the FDA Oncologic Drugs Advisory Committee will review data supporting the Biologics License Application for ABP 215, a biosimilar candidate to Avastin (bevacizumab), an agent sponsored by Genentech, a unit of Roche.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe